Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02640612
Recruitment Status : Completed
First Posted : December 29, 2015
Results First Posted : December 5, 2018
Last Update Posted : December 5, 2018
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Study Type Interventional
Study Design Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition Arthritis, Rheumatoid
Intervention Drug: BI 695501
Enrollment 430
Recruitment Details This study was an open-label extension trial. Adult patients with moderate to severely active rheumatoid arthritis (RA) who completed Trial NCT02137226 (1297.2), wished to participate in this extension trial and per Investigator’s assessment could benefit from continuing to receive BI 695501 were included in this trial.
Pre-assignment Details All patients were screened for eligibility to participate in the trial. The screening visit of this trial was the Week 48 visit in Trial 1297.2.
Arm/Group Title BI 695501 to BI 695501 Humira® to Humira® Humira® to BI 695501
Hide Arm/Group Description Patients initially randomized to BI 695501 in Period 1 and re-randomized to BI 695501 in Period 2 of the 1297.2 trial. Each patient received 40 milligram (mg)/0.8 millilitre (mL) BI 695501 in period 1 and 40 mg/0.8 mL BI 695501 in period 2. The respective treatment was administered by subcutaneous (SC) injection every 2 weeks from Day 1 to Week 48. Patients initially randomized to Humira® in Period 1 and re-randomized to Humira® in Period 2 of the 1297.2 trial. Each patient received 40 mg/0.8 mL Humira® in period 1 and 40 mg/0.8 mL Humira® in period 2. The respective treatment was administered by SC injection every 2 weeks from Day 1 to Week 48. Patients initially randomized to Humira® in Period 1 and re- randomized to BI 695501 in Period 2 of the 1297.2 trial. Each patient received 40 mg/0.8 mL Humira® in period 1 and 40 mg/0.8 mL BI 695501 in period 2. The respective treatment was administered by SC injection every 2 weeks from Day 1 to Week 48.
Period Title: Overall Study
Started 225 103 102
Completed 203 89 96
Not Completed 22 14 6
Reason Not Completed
Adverse Event             6             7             2
Death             1             0             0
Withdrawal by Subject             10             3             3
Lost to Follow-up             4             1             1
Protocol Violation             0             2             0
Lack of Efficacy             1             1             0
Arm/Group Title BI 695501 to BI 695501 Humira® to Humira® Humira® to BI 695501 Total
Hide Arm/Group Description Patients initially randomized to BI 695501 in Period 1 and re-randomized to BI 695501 in Period 2 of the 1297.2 trial. Each patient received 40 milligram (mg)/0.8 millilitre (mL) BI 695501 in period 1 and 40 mg/0.8 mL BI 695501 in period 2. The respective treatment was administered by subcutaneous (SC) injection every 2 weeks from Day 1 to Week 48. Patients initially randomized to Humira® in Period 1 and re-randomized to Humira® in Period 2 of the 1297.2 trial. Each patient received 40 mg/0.8 mL Humira® in period 1 and 40 mg/0.8 mL Humira® in period 2. The respective treatment was administered by SC injection every 2 weeks from Day 1 to Week 48. Patients initially randomized to Humira® in Period 1 and re- randomized to BI 695501 in Period 2 of the 1297.2 trial. Each patient received 40 mg/0.8 mL Humira® in period 1 and 40 mg/0.8 mL BI 695501 in period 2. The respective treatment was administered by SC injection every 2 weeks from Day 1 to Week 48. Total of all reporting groups
Overall Number of Baseline Participants 225 103 102 430
Hide Baseline Analysis Population Description
Safety Analysis Set (SAF): All patients who received at least 1 dose during trial 1297.3. In the event of doubt as to whether a patient was treated or not, they were assumed to have been treated for the purposes of analysis, and thus included in the SAF. Patients were classified according to randomized/re-randomized treatments of Trial 1297.2.
Age, Continuous   [1] [2] 
Mean (Standard Deviation)
Unit of measure:  Years
Number Analyzed 225 participants 103 participants 102 participants 430 participants
53.8  (11.87) 51.7  (11.21) 54.6  (9.90) 53.5  (11.30)
[1]
Measure Description: Age of all patients included in the trial
[2]
Measure Analysis Population Description: SAF
Sex: Female, Male   [1] [2] 
Measure Type: Count of Participants
Unit of measure:  Participants
Number Analyzed 225 participants 103 participants 102 participants 430 participants
Female
188
  83.6%
88
  85.4%
84
  82.4%
360
  83.7%
Male
37
  16.4%
15
  14.6%
18
  17.6%
70
  16.3%
[1]
Measure Description: Gender distribution of all patients included in the trial.
[2]
Measure Analysis Population Description: SAF
Ethnicity (NIH/OMB)   [1] [2] 
Measure Type: Count of Participants
Unit of measure:  Participants
Number Analyzed 225 participants 103 participants 102 participants 430 participants
Hispanic or Latino
23
  10.2%
8
   7.8%
10
   9.8%
41
   9.5%
Not Hispanic or Latino
199
  88.4%
94
  91.3%
92
  90.2%
385
  89.5%
Unknown or Not Reported
3
   1.3%
1
   1.0%
0
   0.0%
4
   0.9%
[1]
Measure Description: Ethnicity of all patients included in the trial
[2]
Measure Analysis Population Description: SAF
Race (NIH/OMB)   [1] [2] 
Measure Type: Count of Participants
Unit of measure:  Participants
Number Analyzed 225 participants 103 participants 102 participants 430 participants
American Indian or Alaska Native
0
   0.0%
0
   0.0%
0
   0.0%
0
   0.0%
Asian
7
   3.1%
2
   1.9%
0
   0.0%
9
   2.1%
Native Hawaiian or Other Pacific Islander
0
   0.0%
0
   0.0%
0
   0.0%
0
   0.0%
Black or African American
3
   1.3%
0
   0.0%
2
   2.0%
5
   1.2%
White
215
  95.6%
100
  97.1%
100
  98.0%
415
  96.5%
More than one race
0
   0.0%
0
   0.0%
0
   0.0%
0
   0.0%
Unknown or Not Reported
0
   0.0%
1
   1.0%
0
   0.0%
1
   0.2%
[1]
Measure Description: Race of all patients included in the trial
[2]
Measure Analysis Population Description: SAF
1.Primary Outcome
Title Percentage of Patients With Drug-related Adverse Events (AEs) During the Treatment Phase
Hide Description The analysis of AEs was based on the concept of treatment-emergent AEs (TEAEs). Thus, all AEs with an onset after the first dose of trial drug up to a period of ten weeks after the last dose of trial drug were assigned to the current treatment for evaluation. Investigator assessed drug related AEs were AEs with a relationship to drug ticked “yes” according to the Investigator.
Time Frame From the first drug administration until 10 weeks after the last drug administration, up to 58 weeks.
Hide Outcome Measure Data
Hide Analysis Population Description
Safety Analysis Set (SAF): All patients who received at least 1 dose during trial 1297.3. In the event of doubt as to whether a patient was treated or not, they were assumed to have been treated for the purposes of analysis, and thus included in the SAF. Patients were classified according to randomized/re-randomized treatments of Trial 1297.2.
Arm/Group Title BI 695501 to BI 695501 Humira® to Humira® Humira® to BI 695501
Hide Arm/Group Description:
Patients initially randomized to BI 695501 in Period 1 and re-randomized to BI 695501 in Period 2 of the 1297.2 trial. Each patient received 40 milligram (mg)/0.8 millilitre (mL) BI 695501 in period 1 and 40 mg/0.8 mL BI 695501 in period 2. The respective treatment was administered by subcutaneous (SC) injection every 2 weeks from Day 1 to Week 48.
Patients initially randomized to Humira® in Period 1 and re-randomized to Humira® in Period 2 of the 1297.2 trial. Each patient received 40 mg/0.8 mL Humira® in period 1 and 40 mg/0.8 mL Humira® in period 2. The respective treatment was administered by SC injection every 2 weeks from Day 1 to Week 48.
Patients initially randomized to Humira® in Period 1 and re- randomized to BI 695501 in Period 2 of the 1297.2 trial. Each patient received 40 mg/0.8 mL Humira® in period 1 and 40 mg/0.8 mL BI 695501 in period 2. The respective treatment was administered by SC injection every 2 weeks from Day 1 to Week 48.
Overall Number of Participants Analyzed 225 103 102
Measure Type: Number
Unit of Measure: Percentage of patients (%)
21.3 20.4 17.6
2.Secondary Outcome
Title Change From Baseline in Disease Activity Score in 28 Joints (DAS 28) by Erythrocyte Sedimentation Rate (ESR) at Week 48
Hide Description The DAS28 (ESR) score was derived using the following formulae: DAS28 (ESR) = 0.56*√(TJC28) + 0.28*√(SJC28) + 0.014*(GH) + 0.7*ln(ESR) Where: • TJC28 = 28 joint count for tenderness • SJC28 = 28 joint count for swelling • GH = General Health component of the DAS (patient’s global assessment of disease activity) • Ln (ESR) = natural logarithm of ESR. Last observation carried forward (LOCF) is the method used for handling missing components post baseline. Baseline for this trial was taken from the baseline of 1297.2. Improvement in DAS28 was also categorized using the European League Against Rheumatism (EULAR) response criteria. The DAS28 provides a number on a scale from 0 to 10 where higher values mean a higher disease activity. A DAS28 above 5.1 means high disease activity whereas a DAS28 below 3.2 indicates low disease activity. Remission is achieved by a DAS28 lower than 2.6.
Time Frame Baseline and Week 48.
Hide Outcome Measure Data
Hide Analysis Population Description
FullAnalysisSet(FAS) includes patients from the all subjects assigned set who received at least 1 dose of trial drug in Trial 1297.3 and had at least 1 DAS28(ESR and C-reactive protein) or american college of rheumatology 20% response criteria (ACR20) measured during trial. Classified according to randomized/rerandomized treatments of trial 1297.2.
Arm/Group Title BI 695501 to BI 695501 Humira® to Humira® Humira® to BI 695501
Hide Arm/Group Description:
Patients initially randomized to BI 695501 in Period 1 and re-randomized to BI 695501 in Period 2 of the 1297.2 trial. Each patient received 40 milligram (mg)/0.8 millilitre (mL) BI 695501 in period 1 and 40 mg/0.8 mL BI 695501 in period 2. The respective treatment was administered by subcutaneous (SC) injection every 2 weeks from Day 1 to Week 48.
Patients initially randomized to Humira® in Period 1 and re-randomized to Humira® in Period 2 of the 1297.2 trial. Each patient received 40 mg/0.8 mL Humira® in period 1 and 40 mg/0.8 mL Humira® in period 2. The respective treatment was administered by SC injection every 2 weeks from Day 1 to Week 48.
Patients initially randomized to Humira® in Period 1 and re- randomized to BI 695501 in Period 2 of the 1297.2 trial. Each patient received 40 mg/0.8 mL Humira® in period 1 and 40 mg/0.8 mL BI 695501 in period 2. The respective treatment was administered by SC injection every 2 weeks from Day 1 to Week 48.
Overall Number of Participants Analyzed 225 103 101
Mean (Standard Deviation)
Unit of Measure: Unit on scale
-3.01  (1.385) -2.91  (1.323) -2.98  (1.218)
3.Secondary Outcome
Title Percentage of Patients Meeting American College of Rheumatology (ACR) 20% Response Criteria at Week 48
Hide Description The proportion of patients meeting the ACR20 response criteria was assessed. A patient had an ACR20 response if all of the following occurred: A ≥ 20 % improvement in the swollen joint count (66 joints), A ≥ 20 % improvement in the tender joint count (68 joints), A ≥ 20 % improvement in at least three of the following assessments: Patient’s assessment of pain, Patient’s global assessment of disease activity (equivalent to the General Health component of the Disease Activity Score ([DAS]), Physician’s global assessment of disease activity, Patient’s assessment of physical function, as measured by the Health Assessment Questionnaire – Disability Index (HAQ-DI) Acute phase reactant (C-reactive protein [CRP]).
Time Frame Week 48.
Hide Outcome Measure Data
Hide Analysis Population Description
FAS, All patients who discontinue treatment, are lost-to-follow-up or have any severe violation related to any therapy that may significantly impact efficacy assessment prior to the secondary endpoint assessment will be considered as a non-responder (NRI).
Arm/Group Title BI 695501 to BI 695501 Humira® to Humira® Humira® to BI 695501
Hide Arm/Group Description:
Patients initially randomized to BI 695501 in Period 1 and re-randomized to BI 695501 in Period 2 of the 1297.2 trial. Each patient received 40 milligram (mg)/0.8 millilitre (mL) BI 695501 in period 1 and 40 mg/0.8 mL BI 695501 in period 2. The respective treatment was administered by subcutaneous (SC) injection every 2 weeks from Day 1 to Week 48.
Patients initially randomized to Humira® in Period 1 and re-randomized to Humira® in Period 2 of the 1297.2 trial. Each patient received 40 mg/0.8 mL Humira® in period 1 and 40 mg/0.8 mL Humira® in period 2. The respective treatment was administered by SC injection every 2 weeks from Day 1 to Week 48.
Patients initially randomized to Humira® in Period 1 and re- randomized to BI 695501 in Period 2 of the 1297.2 trial. Each patient received 40 mg/0.8 mL Humira® in period 1 and 40 mg/0.8 mL BI 695501 in period 2. The respective treatment was administered by SC injection every 2 weeks from Day 1 to Week 48.
Overall Number of Participants Analyzed 225 103 101
Measure Type: Number
Unit of Measure: Percentage of patients (%)
76.9 76.7 73.3
4.Secondary Outcome
Title Percentage of Patients Who Meet the American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) Definition of Remission at Week 48
Hide Description

The ACR/EULAR remission criteria were based on a Boolean definition. At any time point, the patient must have satisfied all of the following:

  • Tender joint count (TJC) ≤ 1
  • Swollen joint count (SJC) ≤ 1
  • C-reactive protein (CRP) ≤ 1 mg/dL
  • Patient global assessment of disease activity ≤ 10 (on a 0 to 100 scale) For TJC and SJC, use of a 28-joint count may have missed actively involved joints, particularly in the feet and ankles. It was preferable to include the feet and ankles when evaluating remission.
Time Frame Week 48.
Hide Outcome Measure Data
Hide Analysis Population Description
FAS
Arm/Group Title BI 695501 to BI 695501 Humira® to Humira® Humira® to BI 695501
Hide Arm/Group Description:
Patients initially randomized to BI 695501 in Period 1 and re-randomized to BI 695501 in Period 2 of the 1297.2 trial. Each patient received 40 milligram (mg)/0.8 millilitre (mL) BI 695501 in period 1 and 40 mg/0.8 mL BI 695501 in period 2. The respective treatment was administered by subcutaneous (SC) injection every 2 weeks from Day 1 to Week 48.
Patients initially randomized to Humira® in Period 1 and re-randomized to Humira® in Period 2 of the 1297.2 trial. Each patient received 40 mg/0.8 mL Humira® in period 1 and 40 mg/0.8 mL Humira® in period 2. The respective treatment was administered by SC injection every 2 weeks from Day 1 to Week 48.
Patients initially randomized to Humira® in Period 1 and re- randomized to BI 695501 in Period 2 of the 1297.2 trial. Each patient received 40 mg/0.8 mL Humira® in period 1 and 40 mg/0.8 mL BI 695501 in period 2. The respective treatment was administered by SC injection every 2 weeks from Day 1 to Week 48.
Overall Number of Participants Analyzed 225 103 101
Measure Type: Number
Unit of Measure: Percentage of patients (%)
8.4 9.7 6.9
5.Secondary Outcome
Title Percentage of Patients With European League Against Rheumatism (EULAR) Response (Good Response, Moderate Response, or no Response) at Week 48
Hide Description

Percentage of patients with European League Against Rheumatism (EULAR) response (good response, moderate response, or no response) were calculated at Week 48 for assessment of this outcome measure.

No response: If improvement in DAS28 (ESR) at w48 <=0.6, or if DAS28(ESR) at w48 >5.1 and improvement is in range >0.6 to <1.2.

Moderate response: If DAS28(ESR) at w48 <=5.1 and improvement is in range >0.6 to <1.2, or, DAS28(ESR) at w48 >3.2 and improvement is in range >=1.2.

Good response: If DAS28(ESR) at w48 <=3.2 and improvement >=1.2.

Time Frame Week 48.
Hide Outcome Measure Data
Hide Analysis Population Description
FAS
Arm/Group Title BI 695501 to BI 695501 Humira® to Humira® Humira® to BI 695501
Hide Arm/Group Description:
Patients initially randomized to BI 695501 in Period 1 and re-randomized to BI 695501 in Period 2 of the 1297.2 trial. Each patient received 40 milligram (mg)/0.8 millilitre (mL) BI 695501 in period 1 and 40 mg/0.8 mL BI 695501 in period 2. The respective treatment was administered by subcutaneous (SC) injection every 2 weeks from Day 1 to Week 48.
Patients initially randomized to Humira® in Period 1 and re-randomized to Humira® in Period 2 of the 1297.2 trial. Each patient received 40 mg/0.8 mL Humira® in period 1 and 40 mg/0.8 mL Humira® in period 2. The respective treatment was administered by SC injection every 2 weeks from Day 1 to Week 48.
Patients initially randomized to Humira® in Period 1 and re- randomized to BI 695501 in Period 2 of the 1297.2 trial. Each patient received 40 mg/0.8 mL Humira® in period 1 and 40 mg/0.8 mL BI 695501 in period 2. The respective treatment was administered by SC injection every 2 weeks from Day 1 to Week 48.
Overall Number of Participants Analyzed 225 103 101
Measure Type: Number
Unit of Measure: Percentage of patients (%)
Good Response 37.8 37.9 41.6
Moderate Response 49.8 54.4 51.5
No Response 9.3 5.8 3.0
Time Frame From the first drug administration until 10 weeks after the last drug administration, up to 58 weeks.
Adverse Event Reporting Description An Adverse Event (AE) was defined as any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. SAF was used for AE assessment.
 
Arm/Group Title BI 695501 to BI 695501 Humira® to Humira® Humira® to BI 695501
Hide Arm/Group Description Patients initially randomized to BI 695501 in Period 1 and re-randomized to BI 695501 in Period 2 of the 1297.2 trial. Each patient received 40 milligram (mg)/0.8 millilitre (mL) BI 695501 in period 1 and 40 mg/0.8 mL BI 695501 in period 2. The respective treatment was administered by subcutaneous (SC) injection every 2 weeks from Day 1 to Week 48. Patients initially randomized to Humira® in Period 1 and re-randomized to Humira® in Period 2 of the 1297.2 trial. Each patient received 40 mg/0.8 mL Humira® in period 1 and 40 mg/0.8 mL Humira® in period 2. The respective treatment was administered by SC injection every 2 weeks from Day 1 to Week 48. Patients initially randomized to Humira® in Period 1 and re- randomized to BI 695501 in Period 2 of the 1297.2 trial. Each patient received 40 mg/0.8 mL Humira® in period 1 and 40 mg/0.8 mL BI 695501 in period 2. The respective treatment was administered by SC injection every 2 weeks from Day 1 to Week 48.
All-Cause Mortality
BI 695501 to BI 695501 Humira® to Humira® Humira® to BI 695501
Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%)
Total   1/225 (0.44%)   0/103 (0.00%)   0/102 (0.00%) 
Show Serious Adverse Events Hide Serious Adverse Events
BI 695501 to BI 695501 Humira® to Humira® Humira® to BI 695501
Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%)
Total   14/225 (6.22%)   8/103 (7.77%)   4/102 (3.92%) 
Cardiac disorders       
Cardiopulmonary failure  1  1/225 (0.44%)  0/103 (0.00%)  0/102 (0.00%) 
Gastrointestinal disorders       
Abdominal pain  1  1/225 (0.44%)  0/103 (0.00%)  0/102 (0.00%) 
Abdominal pain upper  1  0/225 (0.00%)  1/103 (0.97%)  0/102 (0.00%) 
Ileus paralytic  1  1/225 (0.44%)  0/103 (0.00%)  0/102 (0.00%) 
Incarcerated inguinal hernia  1  1/225 (0.44%)  0/103 (0.00%)  0/102 (0.00%) 
Small intestinal obstruction  1  1/225 (0.44%)  0/103 (0.00%)  0/102 (0.00%) 
Umbilical hernia  1  1/225 (0.44%)  0/103 (0.00%)  0/102 (0.00%) 
General disorders       
Non-cardiac chest pain  1  1/225 (0.44%)  0/103 (0.00%)  0/102 (0.00%) 
Hepatobiliary disorders       
Bile duct stenosis  1  0/225 (0.00%)  1/103 (0.97%)  0/102 (0.00%) 
Infections and infestations       
Appendicitis  1  1/225 (0.44%)  0/103 (0.00%)  0/102 (0.00%) 
Clostridium difficile colitis  1  0/225 (0.00%)  0/103 (0.00%)  1/102 (0.98%) 
Gastroenteritis  1  1/225 (0.44%)  0/103 (0.00%)  0/102 (0.00%) 
Otitis media  1  1/225 (0.44%)  0/103 (0.00%)  0/102 (0.00%) 
Pneumonia  1  4/225 (1.78%)  0/103 (0.00%)  0/102 (0.00%) 
Pulmonary tuberculosis  1  0/225 (0.00%)  1/103 (0.97%)  0/102 (0.00%) 
Pyelonephritis chronic  1  1/225 (0.44%)  0/103 (0.00%)  0/102 (0.00%) 
Sepsis  1  1/225 (0.44%)  0/103 (0.00%)  0/102 (0.00%) 
Staphylococcal sepsis  1  0/225 (0.00%)  1/103 (0.97%)  0/102 (0.00%) 
Injury, poisoning and procedural complications       
Femur fracture  1  1/225 (0.44%)  0/103 (0.00%)  0/102 (0.00%) 
Musculoskeletal and connective tissue disorders       
Pathological fracture  1  0/225 (0.00%)  0/103 (0.00%)  1/102 (0.98%) 
Neoplasms benign, malignant and unspecified (incl cysts and polyps)       
Adenocarcinoma of colon  1  1/225 (0.44%)  0/103 (0.00%)  0/102 (0.00%) 
Basal cell carcinoma  1  0/225 (0.00%)  1/103 (0.97%)  0/102 (0.00%) 
Benign soft tissue neoplasm  1  0/225 (0.00%)  1/103 (0.97%)  0/102 (0.00%) 
Ovarian cancer  1  1/225 (0.44%)  0/103 (0.00%)  0/102 (0.00%) 
Reproductive system and breast disorders       
Endometrial hyperplasia  1  1/225 (0.44%)  0/103 (0.00%)  0/102 (0.00%) 
Uterine polyp  1  0/225 (0.00%)  0/103 (0.00%)  1/102 (0.98%) 
Respiratory, thoracic and mediastinal disorders       
Acute respiratory failure  1  1/225 (0.44%)  0/103 (0.00%)  0/102 (0.00%) 
Interstitial lung disease  1  0/225 (0.00%)  1/103 (0.97%)  0/102 (0.00%) 
Skin and subcutaneous tissue disorders       
Henoch-Schonlein purpura  1  0/225 (0.00%)  0/103 (0.00%)  1/102 (0.98%) 
Vascular disorders       
Deep vein thrombosis  1  0/225 (0.00%)  1/103 (0.97%)  0/102 (0.00%) 
Haematoma  1  0/225 (0.00%)  0/103 (0.00%)  1/102 (0.98%) 
1
Term from vocabulary, 15.0
Indicates events were collected by systematic assessment
Show Other (Not Including Serious) Adverse Events Hide Other (Not Including Serious) Adverse Events
Frequency Threshold for Reporting Other Adverse Events 5%
BI 695501 to BI 695501 Humira® to Humira® Humira® to BI 695501
Affected / at Risk (%) Affected / at Risk (%) Affected / at Risk (%)
Total   9/225 (4.00%)   6/103 (5.83%)   2/102 (1.96%) 
Infections and infestations       
Upper respiratory tract infection  1  9/225 (4.00%)  6/103 (5.83%)  2/102 (1.96%) 
1
Term from vocabulary, 15.0
Indicates events were collected by systematic assessment
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.
Results Point of Contact
Layout table for Results Point of Contact information
Name/Title: Boehringer Ingelheim, Call Center
Organization: Boehringer Ingelheim
Phone: 1-800-243-0127
EMail: clintriage.rdg@boehringer-ingelheim.com
Layout table for additonal information
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT02640612     History of Changes
Other Study ID Numbers: 1297.3
2015-002634-41 ( EudraCT Number )
First Submitted: December 18, 2015
First Posted: December 29, 2015
Results First Submitted: October 22, 2018
Results First Posted: December 5, 2018
Last Update Posted: December 5, 2018